



Bux-Mont Endoscopy Center Patient Positive Experience helps Compliance!

As you are all probably aware recent studies published in the nejm (Feb 2012) have lent scientific proof to what has been felt to be true for many years, namely that screening colonoscopy is effective in preventing colon Ca. The study of over 2000 patients followed for 15 years showed a 53% reduction in colon ca mortality in patients undergoing recommended screening. In addition to advances in scope technology and the use of Propofol sedation, the emergence of single specialty endoscopy centers and their emphasis on patient satisfaction have contributed to increased screening rates nationally. The center for disease control reports 58% of Americans between the ages of 50 and 74 years old are adequately screened for colon cancer, still below the 70 % target figure but rising annually. In keeping with these trends Bux-Mont Endoscopy center conducts patient satisfaction surveys of all patients undergoing endoscopy at our center. At discharge, each patient is given a questionnaire requesting their feedback on the care and services provided by the Center. Every patient's input, whether by numeric scale or by notation, is calculated and presented to the staff as part of our Quarterly Quality Assessment Performance Improvement meeting.

For the 6-month period ending in August 2012 we received 276 completed surveys. 99% of the respondents rated their overall experience as good or excellent and 100% rated their confidence in the care provided by the center's staff as good/excellent and said they would recommend to family and friends. Patients are asked what they liked about the center. One recent patient responded: "Organization, compassion, attention to details, professionalism and happy folks. Great doctor—all!"

We plan to continue to monitor this "softer" data and share it with you regularly just as we have the more objective measures of quality colonoscopy (withdraw times, adenoma detection rates and procedure complication rates). We appreciate the trust you show in referring your patients.

BMGI offers Clinical Trials

Bux Mont GI is excited to announce that we are currently enrolling patients in two new phase 3 clinical trials.

The first trial is evaluating a new medication for diarrhea-predominant IBS. Patients with initial symptom onset at least 6 months ago may qualify for this trial. Patients will receive twice daily dosing of study medication or placebo for approximately 6 months, and will complete a daily phone based diary to document their symptoms.

The second trial is studying a new antibiotic for c. difficile-associated diarrhea. Patients with a first or second bout of c.diff may be eligible for this trial, which will randomize patients to the study antibiotic or Vancomycin for a 10 day course. For each trial, enrolled patients will receive the study medication, study-based care, and a travel stipend. Each medication exhibited safety and efficacy in phase 2 trials. Please contact our office at 215-257-3011 if you would like additional information or if you feel that a patient may be interested in either trial.

Colon Cancer Screening Guidelines

<i>Risk</i>	<i>First Colonoscopy</i>	<i>Follow Up Colonoscopy</i>
Average Risk (No Family History of Colon CA or Polyps)	Age 50	Every 10 Years if Negative*
High Risk (One 1st degree relative with Colon CA or Polyps or two 2nd degree relative with Colon CA or Polyps)	Age 40 (earlier in higher risk families)	Every 5 Years if Negative*

*If polyps are found, follow up interval determined by type, number and size of polyps as well as quality of prep.

Our Staff

Jerome Burke, MD, William O'Toole, MD, Michael Cassidy, MD, Ira Kelberman, MD,
Daisy Ortiz, MD, Keith Kearney, DO, Tracey McGinley, CRNP

www.buxmontgi.com

Phone

215-257-3011

Fax

215-257-3437

Location

1107 Bethlehem Pike Sellersville, PA 18960